Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. [electronic resource]
Producer: 20180822Description: 47-59 p. digitalISSN:- 1941-837X
- Adult
- Antibodies, Monoclonal -- economics
- Antineoplastic Combined Chemotherapy Protocols -- economics
- Canada
- Cohort Studies
- Cost-Benefit Analysis
- Female
- Humans
- Male
- Middle Aged
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- diagnosis
- Quality-Adjusted Life Years
- Retrospective Studies
- Risk Assessment
- Rituximab -- economics
- Severity of Illness Index
- Standard of Care -- economics
- Treatment Outcome
No physical items for this record
Publication Type: Evaluation Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.